Related Experiment Video
Updated: Jun 13, 2026

Determining the Toxicity of UV Radiation and Chemicals on Primary and Immortalized Human Corneal Epithelial Cells
Published on: July 22, 2021
[Toxicity of topical ocular anti-allergic agents on human corneal epithelial cells in vitro]
1Department of Ophthalmology, Peking University First Hospital, Beijing 100034, China.
Objective:
To investigate the cytotoxic effect of three kinds of topical ocular anti-allergic agent, including olopatadine 0.1% (A group), ketotifen fumarate 0.025% (B group) and pemirolast potassium 0.1% (C group), on cultured human corneal epithelial cells in vitro.
Methods:
Primary human corneal epithelial cells were cultured with keratinocyte serum-free medium. The cells were exposed to three kinds of topical ocular anti-allergic agent for a period of 10 min, 30 min, 2 h, 6 h, 12 h and 24 h. Toxicity was examined in three ways. MTT assay was used to quantify cytotoxicity. Cell membrane permeability and intracellular esterase activity were analyzed with live-dead viability staining of fluorescent calcein-AM/ethidium homodimer. The morphologic analysis was performed by light and scanning electron microscopy. Statistical methods adopted one-way ANOVA (analysis of variance) and Student-Newman-Keuls q test between each group. The P-value of 0.05 was considered statistically significant.
Results:
(1) Morphologic changes: The Findings under the light microscopy were demonstrated that cells became round or edematic and detached from dishes after exposure to topical ocular anti-allergic agent. The cellular damage was more severe with longer exposure time and increasing concentration. Likewise, the electron microscopy examination showed reduced microvilli with longer exposure time and increasing concentration. The cellular changes of 20.0% olopatadine 0.1% were reduced when compared to the other agents. (2) Live/dead viability/cytotoxicity assay: Ethidium homodimeric permeates damaged cell membranes and results in red fluorescence. These results indicated that cell membrane damage caused by 20.0% olopatadine 0.1% at 6, 12, 24 h was less than those of ketotifen fumarate 0.025% and pemirolast potassium 0.1%. The data of A group were (29.7 +/- 2.6)%, (36.9 +/- 3.2)%, (51.2 +/- 4.3)%, B group were (36.5 +/- 3.1)%, (48.5 +/- 4.3)%, (75.5 +/- 3.8)% and C group were (37.1 +/- 2.2)%, (52.7 +/- 3.4)%, (71.1 +/- 5.1)%, respectively. The q values of A to B group and A to C group at 6 h were 3.27, 4.31, respectively (P < 0.05). The green fluorescent staining of calcein-AM indicated intracellular esterase activity was decreased after incubation with increasing concentration and longer exposure time. There was no significantly different result between each group (P > 0.05). The proportion of green staining cell of A, B and C group at 24 h were 100.0% with 50.0% concentration and were (23.2 +/- 4.6)%, (29.5 +/- 5.2)%, (31.1 +/- 5.5)% respectively with 20.0% concentration (F = 1.97, P = 0.377). (3) MTT assay: The results of the three groups revealed cell viability decreased significantly with increasing concentration and longer exposure time at all the concentrations except 0.8%. MTT values for A, B and C group at the concentration of 20.0%, at 6 h were 0.429 +/- 0.028, 0.367 +/- 0.038, 0.379 +/- 0.012 and 4% at 24 h were 0.457 +/- 0.025, 0.401 +/- 0.008, 0.387 +/- 0.012, respectively. The data for olopatadine 0.1% were significantly improved over those of ketotifen fumarate 0.025% and pemirolast potassium 0.1%. The q value of A to B group, A to C group were 3.01, 3.77 (P < 0.05) at the concentration of 20.0%, 6 h and were 3.63, 4.11 (P < 0.05) at the concentration, 24 h. There were no statistical significant results at other concentrations.
Conclusions:
The topical ocular anti-allergic agent, olopatadine 0.1%, showed less toxic effects on human corneal epithelial cells compared to ketotifen fumarate 0.025% and pemirolast potassium 0.1%. Olopatadine 0.1% may offer a safer option to the corneal epithelium when used to treat allergic keratoconjunctivitis over an extended period of time.
Insights
Olopatadine 0.1% eye drops demonstrated reduced toxicity to human corneal epithelial cells compared to ketotifen fumarate 0.025% and pemirolast potassium 0.1%. This suggests olopatadine may be a safer choice for treating allergic conjunctivitis long-term.
Area of Science:
- Ophthalmology
- Cell Biology
- Toxicology
Context:
- Allergic keratoconjunctivitis requires topical anti-allergic agents.
- Evaluating the in vitro safety of these agents on corneal cells is crucial.
- Olopatadine, ketotifen fumarate, and pemirolast potassium are common treatments.
Purpose:
- To compare the in vitro cytotoxic effects of olopatadine 0.1%, ketotifen fumarate 0.025%, and pemirolast potassium 0.1% on human corneal epithelial cells.
- To assess cell morphology, membrane permeability, esterase activity, and overall viability.
Summary:
- Human corneal epithelial cells were exposed to the agents for varying durations and concentrations.
- MTT assays and live-dead staining revealed olopatadine 0.1% induced significantly less cell damage and membrane permeability compared to the other agents.
- Morphological analysis also indicated reduced cellular damage with olopatadine.
Impact:
- Olopatadine 0.1% exhibits a more favorable safety profile for corneal epithelial cells in vitro.
- This finding supports olopatadine as a potentially safer therapeutic option for prolonged treatment of allergic keratoconjunctivitis.
- Further clinical studies can validate these in vitro safety observations.
More Related Videos
03:57Evaluating Therapeutic and Chemical Toxicity Using Organ-Cultured Porcine Corneas and Epithelial Wound Healing
Published on: January 10, 2025
06:29Effect of Artificial Tear Formulations on the Metabolic Activity of Human Corneal Epithelial Cells after Exposure to Desiccation
Published on: May 2, 2020